EPH154 Assessment of Performance Characteristics of COVID-19 ICD-10-CM Diagnosis Code U07.1 Using Sars-COV-2 Nucleic Acid Amplification Test Results in the US FDA Best Network

K Moll,S Hobbi,Ck Zhou,K Fingar,T Burrell,V Hernandez-Medina,N Alawar,Sa Anderson,Hl Wong,J Obidi,A Shoaibi

doi:10.1016/j.jval.2022.04.905

EPH154 Assessment of Performance Characteristics of COVID-19 ICD-10-CM Diagnosis Code U07.1 Using Sars-COV-2 Nucleic Acid Amplification Test Results in the US FDA Best Network

K Moll, S Hobbi + Show 9 more

Open Access

https://doi.org/10.1016/j.jval.2022.04.905

Copy DOI

Journal: Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research	Publication Date: Jun 25, 2022
License type: NO-CC CODE

Affiliation: IBM (United States), Center for Biologics Evaluation and Research, United States Food and Drug Administration

#Severe Acute Respiratory Syndrome Coronavirus 2 #Identifying COVID-19 Cases + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

EPH154 Assessment of Performance Characteristics of COVID-19 ICD-10-CM Diagnosis Code U07.1 Using Sars-COV-2 Nucleic Acid Amplification Test Results in the US FDA Best Network

Full Text